Genprex Launch IPO For Trials Of New Gene Therapy Lung Cancer Treatment

The company is raising capital to pay the costs of further clinical trials, as the cost of these trials is very high. The earliest that Oncoprex could be available to patients is two years after raising the capital in this IPO.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: NYSE:MRK NYSE:BMY Source Type: news